{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:41:41Z","timestamp":1753882901834,"version":"3.41.2"},"reference-count":13,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p> Paclitaxel is a drug frequently used in the treatment of gynecological cancers. Its cutaneous side effects are fairly well documented. A subtype of hand-foot syndrome, periarticular erythema of the thenar eminences with onycholysis, is rarer. Here, we present a case of a woman treated with paclitaxel for recurrent ovarian cancer who developed periarticular thenar eminence erythema with onycholysis syndrome. Involvement presented as an erythematous rash on the top of the left hand progressing up the arm. A lesion was also present on the right lower limb and on the dorsal surface of the right foot with onycholysis. Edema was present in the fingers, hands, forearms, and feet. A punch biopsy and pathological analysis confirmed the diagnosis of periarticular thenar eminence erythema with onycholysis syndrome. Rapid identification and treatment with topical corticosteroids limited irreversible damage. <\/jats:p>","DOI":"10.1177\/2050313x231213930","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:48:27Z","timestamp":1700650107000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Paclitaxel-induced periarticular thenar eminence erythema with onycholysis: A case report"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8001-829X","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Charron-Ligez","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"D\u00e9sy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cellular Biology, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Auclair","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, H\u00f4pital Maisonneuve-Rosemont, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"volume-title":"TAXOL(R) IV injection, paclitaxel IV injection","year":"2010","author":"Product Information","key":"bibr1-2050313X231213930"},{"key":"bibr2-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.019"},{"key":"bibr3-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2020.442"},{"key":"bibr4-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2015.09.003"},{"key":"bibr5-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618776911"},{"key":"bibr6-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.033"},{"key":"bibr7-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14040"},{"key":"bibr8-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213475466"},{"key":"bibr9-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05782.x"},{"key":"bibr10-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1641-9"},{"key":"bibr11-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833"},{"key":"bibr12-2050313X231213930","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1420912"},{"key":"bibr13-2050313X231213930","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (2017, accessed 3 April 2023)."}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231213930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X231213930","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X231213930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T21:45:37Z","timestamp":1737755137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X231213930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":13,"alternative-id":["10.1177\/2050313X231213930"],"URL":"https:\/\/doi.org\/10.1177\/2050313x231213930","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"type":"print","value":"2050-313X"},{"type":"electronic","value":"2050-313X"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"2050313X231213930"}}